Targeting Nrf2 may reverse the drug resistance in ovarian cancer

BACKGROUND: Acquired resistance to therapeutic drugs has become an important issue in treating ovarian cancer. Studies have shown that the prevalent chemotherapy resistance (cisplatin, paclitaxel etc.) for ovarian cancer occurs partly because of decreased production of reactive oxygen species within...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Danjie, Hong, Xiaoling, Zhao, Feijie, Ci, Xinxin, Zhang, Songling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890806/
https://www.ncbi.nlm.nih.gov/pubmed/33596893
http://dx.doi.org/10.1186/s12935-021-01822-1
_version_ 1783652571608514560
author Li, Danjie
Hong, Xiaoling
Zhao, Feijie
Ci, Xinxin
Zhang, Songling
author_facet Li, Danjie
Hong, Xiaoling
Zhao, Feijie
Ci, Xinxin
Zhang, Songling
author_sort Li, Danjie
collection PubMed
description BACKGROUND: Acquired resistance to therapeutic drugs has become an important issue in treating ovarian cancer. Studies have shown that the prevalent chemotherapy resistance (cisplatin, paclitaxel etc.) for ovarian cancer occurs partly because of decreased production of reactive oxygen species within the mitochondria of ovarian cancer cells. MAIN BODY: Nuclear erythroid-related factor-2 (Nrf2) mainly controls the regulation of transcription of genes through the Keap1-Nrf2-ARE signaling pathway and protects cells by fighting oxidative stress and defending against harmful substances. This protective effect is reflected in the promotion of tumor cell growth and their resistance to chemotherapy drugs. Therefore, inhibition of the Nrf2 pathway may reverse drug resistance. In this review, we describe the functions of Nrf2 in drug resistance based on Nrf2-associated signaling pathways determined in previous studies. CONCLUSIONS: Further studies on the relevant mechanisms of Nrf2 may help improve the outcomes of ovarian cancer therapy.
format Online
Article
Text
id pubmed-7890806
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78908062021-02-22 Targeting Nrf2 may reverse the drug resistance in ovarian cancer Li, Danjie Hong, Xiaoling Zhao, Feijie Ci, Xinxin Zhang, Songling Cancer Cell Int Review BACKGROUND: Acquired resistance to therapeutic drugs has become an important issue in treating ovarian cancer. Studies have shown that the prevalent chemotherapy resistance (cisplatin, paclitaxel etc.) for ovarian cancer occurs partly because of decreased production of reactive oxygen species within the mitochondria of ovarian cancer cells. MAIN BODY: Nuclear erythroid-related factor-2 (Nrf2) mainly controls the regulation of transcription of genes through the Keap1-Nrf2-ARE signaling pathway and protects cells by fighting oxidative stress and defending against harmful substances. This protective effect is reflected in the promotion of tumor cell growth and their resistance to chemotherapy drugs. Therefore, inhibition of the Nrf2 pathway may reverse drug resistance. In this review, we describe the functions of Nrf2 in drug resistance based on Nrf2-associated signaling pathways determined in previous studies. CONCLUSIONS: Further studies on the relevant mechanisms of Nrf2 may help improve the outcomes of ovarian cancer therapy. BioMed Central 2021-02-17 /pmc/articles/PMC7890806/ /pubmed/33596893 http://dx.doi.org/10.1186/s12935-021-01822-1 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Li, Danjie
Hong, Xiaoling
Zhao, Feijie
Ci, Xinxin
Zhang, Songling
Targeting Nrf2 may reverse the drug resistance in ovarian cancer
title Targeting Nrf2 may reverse the drug resistance in ovarian cancer
title_full Targeting Nrf2 may reverse the drug resistance in ovarian cancer
title_fullStr Targeting Nrf2 may reverse the drug resistance in ovarian cancer
title_full_unstemmed Targeting Nrf2 may reverse the drug resistance in ovarian cancer
title_short Targeting Nrf2 may reverse the drug resistance in ovarian cancer
title_sort targeting nrf2 may reverse the drug resistance in ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890806/
https://www.ncbi.nlm.nih.gov/pubmed/33596893
http://dx.doi.org/10.1186/s12935-021-01822-1
work_keys_str_mv AT lidanjie targetingnrf2mayreversethedrugresistanceinovariancancer
AT hongxiaoling targetingnrf2mayreversethedrugresistanceinovariancancer
AT zhaofeijie targetingnrf2mayreversethedrugresistanceinovariancancer
AT cixinxin targetingnrf2mayreversethedrugresistanceinovariancancer
AT zhangsongling targetingnrf2mayreversethedrugresistanceinovariancancer

Ejemplares similares